SynthesisBMC cancer2026
Meta-analysis reveals pathological complete response benefits from neoadjuvant immuno-chemotherapy combination in patients with HER2-negative breast cancer.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis meta-analysis aims to evaluate the pooled pathological complete response (pCR) rate and the relative benefits across different subgroups in human epidermal growth factor receptor 2 (HER2) -negative breast cancer treated with immunotherapy.
methodsClinical trials for neoadjuvant immunotherapy in combination with chemotherapy were identified. The pooled pCR rate of total population and patients across different subgroups was performed.
resultsTotally, the meta-analysis included 15 clinical trials comprising 3,885 patients. The pooled pCR rate was 58% (95% CI, 54-62) for triple-negative breast cancer (TNBC) patients and 25% (95% CI, 22-27) for hormone receptor (HR)-positive/HER2-negative (HR+HER2-) patients, respectively. However, the relative benefit of neoadjuvant chemotherapy combined with immunotherapy compared to chemotherapy was comparable (p = 0.70), with odds ratio (OR) of 1.76 (95% CI, 1.43-2.17) in TNBC patients and 1.87 (95% CI, 1.49-2.36) in HR+HER2- patients. Subgroup analysis showed that programmed cell death ligand-1 (PD-L1)-positive patients had higher pCR benefits compared to PD-L1-negative patients, regardless of whether it was immunotherapy combined with neoadjuvant chemotherapy or neoadjuvant chemotherapy alone, with OR of 3.41 (2.61-4.45) and 2.48 (1.80-3.42) respectively. Conversely, among patients receiving chemotherapy alone, the pCR rate in lymph node-positive cases was 42% lower than that in lymph node-negative cases, while the addition of immunotherapy enabled lymph node-positive patients to achieve a comparable pCR rate to lymph node-negative patients (OR, 1.08).
conclusionImmunotherapy showed substantial benefits in improving pCR rates in both TNBC and HR+HER2- patients when combined with neoadjuvant chemotherapy, especially in lymph node-positive breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.